[1] |
Bavle RM, Venugopal R, Konda P,et al. Molecular classification of oral squamous cell carcinoma[J]. J Clin Diagn Res, 2016, 10(9):ZE18-ZE21. DOI: 10.7860/JCDR/2016/19967.8565.
|
[2] |
Zanoni DK, Montero PH, Migliacci JC,et al. Survival outcomes after treatment of cancer of the oral cavity(1985-2015)[J]. Oral Oncol, 2019, 90:115-121. DOI: 10.1016/j.oraloncology.2019.02.001.
|
[3] |
Gómez-Valenzuela F, Escobar E, Pérez-Tomás R,et al. The inflammatory profile of the tumor microenvironment,orchestrated by cyclooxygenase-2,promotes epithelial-mesenchymal transition[J]. Front Oncol, 2021, 11:686792. DOI: 10.3389/fonc.2021.686792
|
[4] |
Tudor DV, Bâldea I, Lupu M,et al. COX-2 as a potential biomarker and therapeutic target in melanoma[J]. Cancer Biol Med, 2020, 17(1):20-31. DOI: 10.20892/j.issn.2095-3941.2019.0339.
|
[5] |
Santoro A, Bufo P, Russo G,et al. Expression and clinical implication of cyclooxygenase-2 and E-cadherin in oral squamous cell carcinomas[J]. Cancer Biol Ther, 2020, 21(8):667-674. DOI: 10.1080/15384047.2015.1071741.
|
[6] |
Sharma Y, Bala K. Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma[J]. Oncol Rev, 2020, 14(1):456. DOI: 10.4081/oncol.2020.456.
|
[7] |
Pisani LP, Estadella D, Ribeiro DA. The role of Toll like receptors(TLRs)in oral carcinogenesis[J]. Anticancer Res, 2017, 37(10):5389-5394. DOI: 10.21873/anticanres.11965.
|
[8] |
Meliţ LE, Mărginean CO, Mărginean CD,et al. The relationship between Toll-like receptors and Helicobacter pylori-related gastropathies:Still a controversial topic[J]. J Immunol Res, 2019, 2019:8197048. DOI: 10.1155/2019/8197048.
|
[9] |
Ji XK, Madhurapantula SV, He G,et al. Genetic variant of cyclooxygenase-2 in gastric cancer:More inflammation and susceptibility[J]. World J Gastroenterol, 2021, 27(28):4653-4666. DOI: 10.3748/wjg.v27.i28.4653.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
Gao C, Qiao T, Yuan S,et al. The preliminary study for postoperative radiotherapy survival associated with RUNX3 and TLR9 expression in lung cancer[J]. Cancer Manag Res, 2021, 13:4497-4507. DOI: 10.2147/CMAR.S305452.
|
[14] |
Javaid N, Choi S. Toll-like receptors from the perspective of cancer treatment[J]. Cancers(Basel), 2020, 12(2):297. DOI: 10.3390/cancers12020297.
|
[15] |
Hasnat S, Hujanen R, Nwaru BI,et al. The prognostic value of Toll-like receptors in head and neck squamous cell carcinoma:A systematic review and meta-analysis[J]. Int J Mol Sci, 2020, 21(19):7255. DOI: 10.3390/ijms21197255.
|
[16] |
Daskalopoulos AG, Avgoustidis D, Chaisuparat R,et al. Assessment of TLR4 and TLR9 signaling and correlation with human papillomavirus status and histopathologic parameters in oral tongue squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(5):493-513. DOI: 10.1016/j.oooo.2020.01.001.
|
[17] |
|
[18] |
Nasry WHS, Rodriguez-Lecompte JC, Martin CK. Role of COX-2/PGE2 mediated inflammation in oral squamous cell carcinoma[J]. Cancers(Basel), 2018, 10(10):348. DOI: 10.3390/cancers10100348.
|
[19] |
Soares CD, Hernandez-Guerrero JC, Andrade BA,et al. Comparative expression of cyclooxygenase 2 and Ki67 in amelanotic and conventional oral melanoma[J]. Med Oral Patol Oral Cir Bucal, 2020, 25(6):e728-e731. DOI: 10.4317/medoral.23737.
|
[20] |
阮宁,李文超. COX-2在口腔颌面部上皮性肿瘤中的研究进展[J].现代口腔医学杂志,2017,31(3):169-171.
|
[21] |
de Lima MAP, Cavalcante RB, da Silva CGL,et al. Evaluation of HPV and EBV in OSCC and the expression of p53,p16,E-cadherin,COX-2,MYC,and MLH1[J]. Oral Dis, 2021:13814. DOI: 10.1111/odi.13814.
|
[22] |
Siddique AB, Kilgore PCSR, Tajmim A,et al.(-)-Oleocanthal as a dual c-MET-COX2 inhibitor for the control of lung cancer[J]. Nutrients, 2020, 12(6):1749. DOI: 10.3390/nu12061749.
|
[23] |
Xu YQ, Long X, Han M,et al. Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer:A systematic review and meta-analysis[J]. World J Clin Cases, 2021, 9(3):581-601. DOI: 10.12998/wjcc.v9.i3.581.
|
[24] |
Frejborg E, Salo T, Salem A. Role of cyclooxygenase-2 in head and neck tumorigenesis[J]. Int J Mol Sci, 2020, 21(23):9246. DOI: 10.3390/ijms21239246.
|
[25] |
Rahman MA, Tan ML, Johnson SP,et al. Deregulation of lysophosphatidic acid metabolism in oral cancer promotes cell migration via the up-regulation of COX-2[J]. Peer J, 2020, 8:e10328. DOI: 10.7717/peerj.10328.
|
[26] |
Chiang KH, Shieh JM, Shen CJ,et al. Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4[J]. Cancer Sci, 2020, 111(6):2004-2015. DOI: 10.1111/cas.14400.
|
[27] |
Eed EM, Hawash YA, Khalifa AS,et al. Association of Toll-like receptors 2,4,9 and 10 genes polymorphisms and Helicobacterpylori-related gastric diseases in Saudi patients[J]. Indian J Med Microbiol, 2020, 38(1):94-100. DOI: 10.4103/ijmm.IJMM_20_164.
|
[28] |
|
[29] |
Zhang Y, Li Y, Li Y,,et al. Chloroquine inhibits MGC803 gastric cancer cell migration via the Toll-like receptor 9/nuclear factor kappa B signaling pathway[J]. Mol Med Rep, 2015, 11(2):1366-1371. DOI: 10.3892/mmr.2014.2839.
|
[30] |
Echizen K, Hirose O, Maeda Y,et al. Inflammation in gastric cancer:Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways[J]. Cancer Sci, 2016, 107(4):391-397. DOI: 10.1111/cas.12901.
|
[31] |
Mohamed FEZ, Jalan R, Minogue S,et al. Inhibition of TLR7 and TLR9 reduces human cholangiocarcinoma cell proliferation and tumor development[J]. Dig Dis Sci, 2021. DOI: 10.1007/s10620-021-06973-9.
|
[32] |
Zuhrotun Nisa F, Astuti M, Mubarika Haryana S,et al. Effect of papaya leaves( Carica papaya L.)extract on immune response (TLR-7,TLR-9)and inflammation(COX-2)in rats induces DMBA(7,12-dimethylbenz[a]antrasen)[J]. Pak J Biol Sci, 2020, 23(11):1450-1455. DOI: 10.3923/pjbs.2020.1450.1455.
|
[33] |
Rich AM, Hussaini HM, Parachuru VPB,et al. Toll-like receptors and cancer,particularly oral squamous cell carcinoma[J]. Front Immunol, 2014, 5:464. DOI: 10.3389/fimmu.2014.00464.
|
[34] |
Pu D, Yin L, Huang L,et al. Cyclooxygenase-2 inhibitor:A potential combination strategy with immunotherapy in cancer[J]. Front Oncol, 2021, 11:637504. DOI: 10.3389/fonc.2021.637504.
|